[New somatostatin analogue 99mTc-HYNIC-TOC in the scintigraphic diagnosis of medullary thyroid carcinoma].
Medullary thyroid carcinoma (MTC) origins from parafollicular cells and secretes calcitonin. It accounts for 5-10% of malignant thyroid tumors. In MTC, radionuclide imaging is employed as complementary method in addition to the routine radiological procedures. Especially, scintigraphy using labelled peptides that specifically bind to the somatostatin receptors is used. Recently a somatostatin analogue labelled with 99mTc (99mTc-HYNIC-TOC) was synthetized. As shown in previous studies, it has favourable pharmacokinetic and clinical characteristics. Aim of this study was to evaluate the utility of 99mTc-HYNIC-TOC in the radionuclide imaging in patients in different stages of MTC. 32 patients in following stages of the disease were studied: evaluation before thyroidectomy (6 patients), remission after surgical treatment (5 patients), stagnation or recurrence after surgical therapy (21 patients). The classification was based on the calcitonin concentrations. The study group included 19 women and 13 men aged 14 to 83 years. Whole body scintigraphy was performed twice: 2 and 4 hours after injection of 20 mCi 99mTc-HYNIC-TOC using dual-head Varicam gamma camera (Elscint). The obtained results were compared to the clinical data and other employed imaging modalities. The scintigraphy using 99mTc-HYNIC-TOC showed 20 true positive, 4 true negative, 1 false positive and 7 false negative results. The sensitivity of this method was 74,1% and specificity - 80,0%. These results are better than those obtained by other authors using other imaging methods. The current study showed high utility of the new peptide tracer in the diagnosis of MTC. Its diagnostic accuracy allows us to recommend it for diagnosis and treatment planning (including radionuclide therapy) in patients with MTC on the routine basis.